Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from NervGen Pharma ( (NGEN) ) is now available.
NervGen Pharma reported its full-year 2025 results and outlined progress on its NVG-291 program, highlighting positive Phase 1b/2a CONNECT SCI data in chronic tetraplegia that showed statistically significant improvements in corticospinal connectivity and functional hand use, with durable benefits beyond the treatment period. The company has completed an End-of-Phase 2 meeting with the FDA and, supported by multiple potential regulatory pathways and a recent Nasdaq listing, plans to initiate a Phase 3 trial in mid-2026, present further biomechanical gait data, and prioritize expansion of NVG-291 into additional neurotraumatic and neurologic indications, reinforcing its ambition to emerge as a leader in neuroreparative therapeutics.
The most recent analyst rating on (NGEN) stock is a Buy with a $6.75 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the NGEN Stock Forecast page.
More about NervGen Pharma
NervGen Pharma is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. The company is advancing its lead candidate NVG-291, targeting chronic and subacute tetraplegia, and aims to expand into additional indications based on extensive preclinical efficacy data.
Average Trading Volume: 139,305
Technical Sentiment Signal: Buy
Current Market Cap: $294.4M
For an in-depth examination of NGEN stock, go to TipRanks’ Overview page.